Última actualização :
18/04/2024
Antifúngico   Caspofungin acetate  
Injetável
Solução oftálmica
Estabilidade em soluções simples Estabilidade em misturas Factores que afectam a sua estabilidade Compatibilidade Método de administração Bibliografía Pdf
   Estrutura química  

Nomes comerciais nos diversos países   Nomes comerciais nos diversos países     

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Afundas Turquia
Cagin Peru
Cancidas Alemanha, Arábia Saudita, Argentina, Australia, Bélgica, Brasil, Canadá, Chilli, Colômbia, Dinamarca, Emirados Árabes Unidos, Equator, Estados Unidos de América, Finlandia, França, Gran-bretanha, Hungria, Índia, Irã, Irlanda, Islandia, Itália, Japón, Luxemburgo, Malásia, México, Noruega, Nova Zelândia, Peru, Portugal, Romènia, Suècia, Suicia, Turquia
Casfucid Chilli, Equator, Peru
Casfung Equator, Índia
Caspodyan Chilli
Caspofungin Alemanha, Australia, Austria, Dinamarca, Estados Unidos de América, Finlandia, Gran-bretanha, Grècia, Hungria, Irlanda, Itália, Japón, Luxemburgo, Noruega, Países Baixos, Polonia, Suicia
Caspofungina Brasil, Chilli, Equator, Espanha
Caspogin Índia
Caspopharm Peru
Casporan Índia
Caspovitae Chilli, Peru
Driken Peru
Fentex Chilli
Fhanigun México
Fungidas Turquia
Monmix México
Sanicid Chilli
Suvepur Chilli, México
Ucaspo Equator
Bibliografía   Injetável   Bibliografía : Caspofungin acetate  
Tipo Publicação
1519 Laboratório Caspofungine (Cancidas®) - Summary of Product Characteristics
Merck Sharp Dohme 2015
2017 Jornal Barker B, Feddema S, Rusho WJ, Dengg R.
Visual compatibility of vasopressin with other injectable drugs.
Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2233 Jornal Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Jornal Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Jornal Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Jornal Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012 Jornal Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3140 Jornal Tsiouris M, Ulmer M, Yurcho J F, Hooper K L, Gui M.
Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device.
Int J Pharm Compound 2010 ; 14, 5 : 436-439.
3216 Jornal Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Jornal Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Jornal Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408 Jornal Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3728 Jornal Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766 Jornal Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Jornal Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3964 Jornal Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3976 Jornal Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055 Jornal Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4067 Jornal Pinder N, Pelzl L.H; Walther G, Backhaus J, Kurzai O, Hoppe-Ticky T.
Caspofungin infusion solutions (50 mg/mL): chemical stability and antifungal activity against Candida spp.
Pharmazie 2017 ;72:197-199
4145 Jornal Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Jornal Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4380 Laboratório Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4528 Jornal Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Jornal Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Laboratório Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4655 Jornal Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33

  Mentions Légales